TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3894707
Drug: Seven-day course
Normalized name: Sevenfact
DrugBank: Coagulation factor VIIa Recombinant Human (DB00036)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seven-day course of 500 mg metronidazole given twice daily
Study: 18084150
Drug: Ongoing prospective
Normalized name: Ongo-Fin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ongoing prospective randomized studies (Surgical Treatment for Ischemic Heart Disease trial, Heart Failure Revascularization trial, PET and Recovery Following Revascularization-2 trial)
Study: 16045667
Drug: Infraclavicular block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infraclavicular block (single injection)
Study: 16045667
Drug: Axillary block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axillary block (multiple injections)
Study: 7872274
Drug: Olsalazine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olsalazine (1 g daily)
Study: 25282519
Drug: Evolocumab 140
Normalized name: evolocumab 140 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab 140 mg every 2 weeks
Study: 28081288
Drug: Short implants
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short implants (6 mm)
Study: 28081288
Drug: Long implants
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long implants (11‐15 mm)
Study: 28081288
Drug: Long implants
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long implants (11‐15 mm) with sinus grafting
Study: 28081288
Drug: Short implants
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short implants (6 mm) with sinus grafting
Study: 23414585
Drug: Ganitumab (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganitumab (12 mg/kg bodyweight) + Fulvestrant (500 mg on day 1, then 250 mg on days 15, 29, and every 28 days)
Study: 23414585
Drug: Ganitumab (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganitumab (12 mg/kg bodyweight) + Exemestane (25 mg once daily)
Study: 23414585
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + Fulvestrant (500 mg on day 1, then 250 mg on days 15, 29, and every 28 days)
Study: 23414585
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + Exemestane (25 mg once daily)
Study: 23414585
Drug: Ganitumab (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganitumab (12 mg/kg bodyweight)
Study: 19118617
Drug: Shi-Bi-Lin (SBL)
Normalized name: bis-ethoxydiglycol succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shi-Bi-Lin (SBL) capsules
Study: 16500713
Drug: Amphetamine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amphetamine (30 mg)
Study: 14693608
Drug: Electric needle
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electric needle acupuncture over 15 min at analgesic points of the leg (n = 8)
Study: 14693608
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (n = 8)
Study: 11020090
Drug: Mindfulness meditation-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness meditation-based stress reduction program (weekly meditation group lasting 1.5 hours for 7 weeks plus home meditation practice)
Study: 9362436
Drug: Gallium nitrate
Normalized name: Gallium Nitrate
DrugBank: Gallium citrate (DB17893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gallium nitrate (40 mg administered as a subcutaneous injection once daily for 2 weeks, followed by 2 weeks off treatment, recycled monthly)
Study: 27619354
Drug: Multifaceted intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multifaceted intervention including education, guideline development, elimination of recurring laboratory orders, unbundling of laboratory panels, redesign of the daily progress note.
Study: 26276164
Drug: Local infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local infiltration analgesia (LIA) - 150 ml ropivacaine 0.2 % with epinephrine intra‐operatively
Study: 26276164
Drug: Interscalene brachial
Normalized name: Brachiara mutica pollen
DrugBank: Urochloa mutica pollen (DB10716)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interscalene brachial plexus catheter (ISC) - ropivacaine 0.75 %, 7 ml bolus followed by 48‐h 5 ml/h infusion
Study: 21143256
Drug: Predefined pharmacist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Predefined pharmacist intervention focusing on correct medication use, medication adherence, and healthy lifestyle promotion
Study: 21143256
Drug: Predefined pharmacist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Predefined pharmacist intervention with sustained pharmacotherapy changes
Study: 15598919
Drug: Implantable cardioverter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implantable cardioverter defibrillator (ICD) or combined cardiac resynchronization therapy and defibrillator (CRT-D)
Study: 15598919
Drug: All trials
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All trials combined (ICD therapy)
Study: 10021718
Drug: 200 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/kg porcine surfactant (Group A)
Study: 10021718
Drug: 100 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/kg porcine surfactant (Group B)
Study: 10021718
Drug: 200 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/kg porcine surfactant (Group A) in subgroup < 1500 grams
Study: 10021718
Drug: 100 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/kg porcine surfactant (Group B) in subgroup < 1500 grams
Study: 8402378
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of IVD and traditional instruction
Study: 3490270
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of propofol during nitrous oxide anaesthesia
Study: 25626738
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anaesthesia (TIVA) with propofol/remifentanil
Study: 24337423
Drug: Interdisciplinary functional
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interdisciplinary functional restoration treatment with cognitive behavior therapy
Study: 16740371
Drug: MRgFUS without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MRgFUS without pre-treatment
Study: 9915271
Drug: 1.0 mmol/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mmol/L dialysate calcium solution
Study: 9915271
Drug: 1.25 mmol/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mmol/L dialysate calcium solution
Study: 8525396
Drug: Praziquantel (25mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel (25mg/kg body weight in one dose)
Study: 2305760
Drug: Successful transplantation
Normalized name: Washed Microbiota Transplantation
DrugBank: Washed Microbiota Transplantation (DB15745)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Successful transplantation (cyclosporine/prednisone therapy, N = 51)
Study: 2305760
Drug: Successful transplantation
Normalized name: Washed Microbiota Transplantation
DrugBank: Washed Microbiota Transplantation (DB15745)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Successful transplantation (conventional immunosuppressive therapy; antilymphocyte globulin/prednisone/azathioprine, N = 40)
Study: 7023415
Drug: Men's group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Men's group treatment for erectile dysfunction
Study: 25317790
Drug: Ibuprofen 10
Normalized name: ibuprofen 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 10 mg/kg, followed by 5 mg/kg after 24 and 48 hours
Study: 22638934
Drug: Short-course radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course radiotherapy (SC-RT) 29 Gy in 10 twice daily fractions followed by immediate surgery; n=108
Study: 22638934
Drug: Long-course radiochemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-course radiochemotherapy (LC-RCHT) 54 Gy in 28 fractions with simultaneous 5-fluorouracil (5-FU) ± oxaliplatin chemotherapy followed by delayed surgery; n=117
Study: 17084393
Drug: GnRH‐agonist/rFSH
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRH‐agonist/rFSH
Study: 17084393
Drug: GnRH‐antagonist/rFSH
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRH‐antagonist/rFSH
Study: 8207601
Drug: Intracordal injection
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracordal injection therapy with atelocollagen (submucosal injection)
Study: 8207601
Drug: Intracordal injection
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracordal injection therapy with atelocollagen (intramuscular injection)
Study: 2563321
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg pirbuterol thrice daily
Study: 4607845
Drug: Ancrod therapy
Normalized name: ancrod
DrugBank: Ancrod (DB05099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ancrod therapy
Study: 29855660
Drug: 4-fluoroamphetamine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-fluoroamphetamine (100 mg)
Study: 23391831
Drug: Scaling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling and root planing (SRP) plus 0.5% AZM gel
Study: 19663110
Drug: Oligopeptide (Lumixyl)
Normalized name: oligopeptide 104
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oligopeptide (Lumixyl) 0.01% w/w, applied twice daily for 16 weeks
Study: 14724157
Drug: Synbiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synbiotic therapy (Lactobacillus acidophilus La5, Bifidobacterium lactis Bb‐12, Streptococcus thermophilus, Lactobacillus bulgaricus, and oligofructose)
Study: 14724157
Drug: Placebo (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (placebo capsules and sucrose powder)
Study: 2549261
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g of ascorbic acid (vitamin C)/day plus 400 mg of alpha‐tocopherol (vitamin E)/day plus 22.5 g/day of grain fiber supplement
Study: 2549261
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g of ascorbic acid (vitamin C)/day plus 400 mg of alpha‐tocopherol (vitamin E)/day alone
Study: 24843060
Drug: 10 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 µg Engerix‐B
Study: 24843060
Drug: 20 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 µg Engerix‐B
Study: 24843060
Drug: Baseline (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline (no challenge dose)
Study: 20146702
Drug: Omeprazole-Mg 20.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole-Mg 20.6 mg
Study: 18434902
Drug: Hydrocortisone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (50 mg single bolus)
Study: 18434902
Drug: Hydrocortisone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (50 mg every 6 hrs) plus Fludrocortisone (50 microg daily)
Study: 10335903
Drug: Troglitazone 200
Normalized name: troglitazone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone 200 mg per day
Study: 10335903
Drug: Troglitazone 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone 600 mg per day
Study: 2165888
Drug: Basal diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal diet with isocaloric addition of 1 g of meat protein day‐1 kg‐1
Study: 26082974
Drug: Adjunct minocycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunct minocycline (100 mg oral capsule twice daily; n = 29)
Study: 26082974
Drug: Adjunct minocycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunct minocycline
Study: 21730224
Drug: 2 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g/d of plant sterols (PS)
Study: 19054288
Drug: Occlusal appliance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occlusal appliance treatment
Study: 16739842
Drug: Jingjin therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jingjin therapy
Study: 15589061
Drug: Allopurinol 100
Normalized name: allopurinol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol 100 mg three times a day for 14 days
Study: 3544782
Drug: Thrombolytic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic treatment (streptokinase) for anterior AMI
Study: 3544782
Drug: Thrombolytic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic treatment (streptokinase) for anterior AMI with Q waves
Study: 3544782
Drug: Thrombolytic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic treatment (streptokinase) for anterior AMI with high ST elevation
Study: 3544782
Drug: Thrombolytic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic treatment for inferior AMI
Study: 3544782
Drug: Thrombolytic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic treatment for inferior AMI with high ST-segment elevation
Study: 3544782
Drug: Thrombolytic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic treatment for inferior AMI with marked contralateral ST-segment depression
Study: 3544782
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment for anterior AMI
Study: 3544782
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment for inferior AMI
Study: 24323062
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (0.9% sodium chloride) solution
Study: 24323062
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (0.9% sodium chloride) solution with added gentamicin (80 mg/L)
Study: 20417857
Drug: Pyronaridine-artesunate (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyronaridine-artesunate (180 mg pyronaridine and 60 mg artesunate once a day for 3 days)
Study: 20417857
Drug: Artemether-lumefantrine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemether-lumefantrine (20 mg artemether and 120 mg lumefantrine twice a day for 3 days)
Study: 11236340
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of piperacillin sodium (2 g i.v. after umbilical cord clamping)
Study: 11236340
Drug: Triple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple doses of piperacillin sodium (2 g i.v. at 6 hourly intervals starting from umbilical cord clamping)
Study: 29762764
Drug: Ethanol 0.6
Normalized name: ethanol 0.6 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol 0.6 g/kg
Study: 29762764
Drug: Ethanol 0.45
Normalized name: FRAGRANCE 13576 0.15 g in 50 mL / GRAPE SEED OIL 0.25 g in 50 mL / GLYCERYL MONOSTEARATE 3.5 g in 50 mL / LINALOOL, (+/-)- 0.0114 g in 50 mL / PHENOXYETHANOL 0.45 g in 50 mL / PROPYLENE GLYCOL 1.5 g in 50 mL / TITANIUM DIOXIDE 0.25 g in 50 mL / PALMITIC ACID 1 g in 50 mL / BUTYLATED HYDROXYTOLUENE 0.25 g in 50 mL / STARCH, RICE 5.5 g in 50 mL / ALCOHOL 4.752 mL in 50 mL / C12-20 ACID PEG-8 ESTER 1 g in 50 mL / TROLAMINE 0.25 g in 50 mL / ISOMETHYL-.ALPHA.-IONONE 0.00639 g in 50 mL / HYDROXYACETOPHENONE 0.25 g in 50 mL / PERLITE 4 g in 50 mL / GLYCERIN 0.0115 g in 50 mL / ETHYLHEXYLGLYCERIN 0.05 g in 50 mL / .BETA.-CITRONELLOL, (R)- 0.012 g in 50 mL / WATER 25.04945 g in 50 mL / STEARIC ACID 1 g in 50 mL / CETEARYL ETHYLHEXANOATE 0.75 g in 50 mL TOPICAL CREAM [Anubis Barcelona Spa Line]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol 0.45 g/kg
Study: 27395380
Drug: Amitriptyline 50
Normalized name: amitriptyline 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline 50 mg/d (25 mg twice daily)
Study: 22700528
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy (IIT) for 24 hours
Study: 22700528
Drug: Usual subcutaneous
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual subcutaneous insulin for 24 hours
Study: 22700528
Drug: Usual subcutaneous
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual subcutaneous insulin
Study: 19776507
Drug: 0.18% isotretinoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.18% isotretinoin applied topically twice a day for one month
Study: 11512369
Drug: Propofol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (2 mg.kg‐1)
Study: 11512369
Drug: Thiopental (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental (5 mg.kg‐1)
Study: 7851104
Drug: Supported employment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supported employment program (changed from day treatment)
Study: 7851104
Drug: Day treatment
Normalized name: Pharmacist Clotrimazole 3 Day Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day treatment program (control)
Study: 29793566
Drug: Resin infiltration
Normalized name: Benzoin resin
DrugBank: Benzoin resin (DB11222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resin infiltration followed by five percent topical sodium fluoride (NaF) application
Study: 24630840
Drug: Tribulus terrestris
Normalized name: TRIBULUS TERRESTRIS
DrugBank: Tribulus terrestris (DB14358)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tribulus terrestris 800 mg, divided into two doses per day for thirty days
Study: 24630840
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered in the same way as the intervention
Study: 12207107
Drug: Non-treatment-resistant depression
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-treatment-resistant depression (non-TRD)
Study: 7053283
Drug: Sulfinpyrazone, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfinpyrazone, 400 mg daily
Study: 7053283
Drug: S-warfarin with
Normalized name: (S)-Warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-warfarin with sulfinpyrazone
Study: 7053283
Drug: R-warfarin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-warfarin with sulfinpyrazone
Study: 27513640
Drug: Epidural 0.125%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural 0.125% ropivacaine with dexmedetomidine (0.5 μg/kg)
Study: 21336156
Drug: Quadruple sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple sequential therapy plus 6 weeks of iron supplementation
Study: 21336156
Drug: Eradication therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eradication therapy plus placebo
Study: 15998749
Drug: 40 g
Normalized name: PEG-40 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g of isolated soybean protein supplements per day
Study: 6343154
Drug: Intravenous maprotiline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous maprotiline (100 mg daily)
Study: 6343154
Drug: Intravenous clomipramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous clomipramine (Anafranil)
Study: 31955859
Drug: Lenvatinib 24
Normalized name: lenvatinib 24 MG Daily Dose 30 Day Supply Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenvatinib 24 mg once daily in a 28-day dosing cycle
Study: 31618331
Drug: Comparison between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison between PAR-G and 1PO-G
Study: 23937679
Drug: Epelsiban 50
Normalized name: Epelsiban
DrugBank: Epelsiban (DB11934)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epelsiban 50 mg
Study: 23937679
Drug: Epelsiban 150
Normalized name: Epelsiban
DrugBank: Epelsiban (DB11934)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epelsiban 150 mg
Study: 17572830
Drug: Melatonin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (3 mg, 1 hour before bedtime)
Study: 17012882
Drug: DTaP‐IPV//PRP‐T combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP‐IPV//PRP‐T combination vaccine (Pentacel) administered as a fourth dose at 15, 16, 17, or 18 months of age.
Study: 17012882
Drug: DTaP‐IPV//PRP‐T combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP‐IPV//PRP‐T combination vaccine (Pentacel) administered as a fourth dose.
Study: 12459073
Drug: pravastatin 10
Normalized name: pravastatin 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: pravastatin 10 mg
Study: 10588407
Drug: ABT-418 (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-418 (75 mg/day)
Study: 24549101
Drug: RG3487 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: RG3487 5 mg
Study: 24549101
Drug: RG3487 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: RG3487 50 mg
Study: 24549101
Drug: RG3487 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: RG3487 15 mg
Study: 22242614
Drug: Preoperative total
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative total parenteral nutrition (TPN) for 18‐90 days (mean, 46 days)
Study: 16174587
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid injection into the amniotic cavity
Study: 16174587
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of compound amino acid
Study: 12037731
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g of glucose
Study: 9638715
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g of mannitol
Study: 12037731
Drug: insulin‐induced hypoglycemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: insulin‐induced hypoglycemia
Study: 10221717
Drug: Relaxin administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxin administration (up to 10 times higher than during pregnancy)
Study: 10221717
Drug: Relaxin administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxin administration
Study: 345342
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg glucagon
Study: 29295829
Drug: Medication therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication therapy management intervention (single home visit by a pharmacist within 7 days of discharge)
Study: 29295829
Drug: Medication therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication therapy management intervention
Study: 27720040
Drug: DHA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA supplementation (high dose)
Study: 27720040
Drug: DHA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA supplementation (low dose)